ArticleJournal of translational medicine2025
Saliva-derived extracellular vesicles: a promising therapeutic approach for salivary gland fibrosis.
Article in Journal of translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Cell and Gene Therapy for Patients Suffering from Xerostomia (Dry Mouth): Positioning Extracellular Vesicles as the Bridge Between Biomarker Discovery and Regenerative Therapy in Xerostomia-A Scoping Review.International journal of molecular sciences · 2026Article
- The synergistic applications of organoids and exosomes in disease modeling and disease treatment.Molecular biology reports · 2026Review
- A Mouthful of Genomic Data: Single-Cell Insights into Salivary Gland Biology and Disease.Biology · 2026Review
- Radiation-Induced Salivary Gland Fibrosis: Mechanisms, Emerging Therapies, and Gelatin-Based Bioengineered Models.Gels (Basel, Switzerland) · 2026Review
- The recent progression of extracellular vesicles application in osteoporosis.Frontiers in pharmacology · 2026Review
- An intricate relationship between fibrosis and autoimmune diseases: a specific focus on unraveling its molecular, immunological, and epigenetic drivers.Frontiers in immunology · 2026Review
- A Narrative Review of Salivary Gland Extracellular Matrix and Sjögren's Syndrome: Research Status and Future Prospects.Biomolecules · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundSalivary gland (SG) fibrosis is characterized by aberrant extracellular matrix deposition and myofibroblast activation, leading to irreversible glandular dysfunction. Current treatments remain ineffective in reversing fibrosis, necessitating novel therapeutic strategies.
methodsWe investigated the anti-fibrotic effects of saliva-derived extracellular vesicles (sEV) through in vitro and in vivo approaches. Histopathological analysis assessed collagen deposition and myofibroblast activation in SG tissues. Human SG fibroblasts (hSGFs) and SG organoids were treated with sEV to evaluate their effects on TGF-β-induced fibrogenic activity, including migration, collagen production, and myofibroblast activation. Network analysis of exosomal miRNAs and integration of RNA sequencing with sEV miRNA-seq were performed to identify key regulatory pathways. A Wharton's duct ligation model was used to examine the therapeutic potential of local sEV administration.
resultssEV treatment significantly attenuated TGF-β-induced fibrogenic activity in hSGFs and SG organoids, suppressing migration, collagen production, and myofibroblast activation. Bioinformatics analysis revealed a synergistic regulatory effect of sEV-derived miRNAs on fibrosis-associated pathways, with STAT3 identified as a key mediator. In vivo, local sEV administration reduced SG fibrosis, preserved acinar structure, and inhibited STAT3 nuclear translocation in fibroblasts.
conclusionOur findings demonstrate that sEV exerts potent anti-fibrotic effects by modulating STAT3 signaling, offering a promising cell-free therapeutic strategy for SG fibrosis. These results highlight the potential of sEV as a natural nanotherapy for fibrotic SG disorders.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.